نتائج البحث - "Pascal Wolter"

1

Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

المساهمون: Kim Y.H., Prince H.M., Whittaker S., Horwitz S.M., Duvic M., Bechter O., Sanches J.A., Stadler R., Scarisbrick J., Quaglino P., Zinzani P.L., Wolter P., Eradat H., Pinter-Brown L.C., Ortiz-Romero P.L., Akilov O.E., Trotman J., Taylor K., Weichenthal M., Walewski J., Fisher D., McNeeley M., Gru A.A., Brown L., Palanca-Wessels M.C., Lisano J., Onsum M., Bunn V., Little M., Trepicchio W.L., Dummer R.

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Lymphoma, Choice Behavior, 0302 clinical medicine, Antineoplastic Agents, Immunological, immune system diseases, Retrospective Studie, hemic and lymphatic diseases, Objective response, 80 and over, Brentuximab vedotin, Cancer, Aged, 80 and over, Brentuximab Vedotin, Mycosis Fungoide, integumentary system, medicine.diagnostic_test, Antibody-drug conjugate, CD30, Cutaneous T-cell lymphoma, Efficacy, Large-cell transformation, Mycosis fungoides, Progression-free survival, Safety, Hematology, Middle Aged, Prognosis, Survival Rate, Immunological, International Agencie, 030220 oncology & carcinogenesis, Public Health and Health Services, Female, medicine.drug, Human, Adult, medicine.medical_specialty, Prognosi, Oncology and Carcinogenesis, Ki-1 Antigen, Antineoplastic Agents, Follow-Up Studie, Decision Support Techniques, 03 medical and health sciences, Young Adult, Rare Diseases, Clinical Research, Internal medicine, Physicians, Biopsy, medicine, Humans, Oncology & Carcinogenesis, Retrospective Studies, Aged, business.industry, International Agencies, medicine.disease, Clinical trial, 030104 developmental biology, Orphan Drug, Physician, business, Follow-Up Studies

وصف الملف: Print-Electronic; STAMPA; application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad3b61df0e6864ee0a19d3ccb015c2ca
https://lirias.kuleuven.be/handle/123456789/674933

2

Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib

المؤلفون: Maxime Vanmechelen, Diether Lambrechts, Maarten Albersen, Jean-Pascal Machiels, Eduard Roussel, Gabrielle Couchy, Jessica Zucman-Rossi, Annelies Verbiest, Reza Elaidi, Philip R. Debruyne, Stéphane Oudard, Benoit Beuselinck, Brigitte Laguerre, Marcella Baldewijns, Vincent Verschaeve, Nathalie Rioux-Leclercq, Vincent Richard, Pascal Wolter, Thomas Van Brussel

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Sunitinib, urogenital system, Single-nucleotide polymorphism, medicine.disease, Correlation, 03 medical and health sciences, Clear cell renal cell carcinoma, 030104 developmental biology, 0302 clinical medicine, Nephrology, 030220 oncology & carcinogenesis, Internal medicine, medicine, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bca60ca367900c620cd5dad0bc88d21
https://lirias.kuleuven.be/handle/123456789/656355

3

Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study

المساهمون: Dummer R., Prince H.M., Whittaker S., Horwitz S.M., Kim Y.H., Scarisbrick J., Quaglino P., Zinzani P.L., Wolter P., Eradat H., Pinter-Brown L., Sanches J.A., Ortiz-Romero P.L., Akilov O.E., Geskin L., Huen A., Walewski J., Wang Y., Lisano J., Richhariya A., Feliciano J., Zhu Y., Bunn V., Little M., Zagadailov E., Dalal M.R., Duvic M., University of Zurich, Dummer, Reinhard

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Skin Neoplasms, Lymphoma, Drug Resistance, 0302 clinical medicine, Quality of life, Surveys and Questionnaires, 80 and over, Medicine, 1306 Cancer Research, Young adult, Brentuximab vedotin, Aged, 80 and over, Bexarotene, Brentuximab Vedotin, 10177 Dermatology Clinic, Middle Aged, Lymphoma, T-Cell, Cutaneous, Clinical trial, Treatment Outcome, Oncology, Local, 030220 oncology & carcinogenesis, 2730 Oncology, Female, medicine.drug, Adult, medicine.medical_specialty, Psychometrics, Cutaneous T-cell lymphoma, 610 Medicine & health, 03 medical and health sciences, Young Adult, Phase III, Internal medicine, Humans, Patient Reported Outcome Measures, Aged, business.industry, CD30, Drug Resistance, Neoplasm, Neoplasm Recurrence, Local, Quality of Life, medicine.disease, T-Cell, Confidence interval, 030104 developmental biology, Cutaneous, Neoplasm Recurrence, Neoplasm, Methotrexate, business

وصف الملف: STAMPA; 871_Dummer_R._et_al._Patient-reported_quality_of_life_in_patients_with_relapsed_refractory_cutaneous_T-cell_lymphoma_EJC_2020.pdf - application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba1a928f402b508b392b16d86bfd0842
http://hdl.handle.net/2318/1815311

4

ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib

المؤلفون: Pascal Wolter, Brigitte Decallonne, Vincent Verschaeve, Philip R. Debruyne, Julie Bastin, Diether Lambrechts, Jean-Pascal Machiels, Thomas Van Brussel, Evelyne Lerut, Vincent Richard, Annelies Verbiest, Oliver Bechter, Patrick Schöffski, Benoit Beuselinck, Emilie Werbrouck

المساهمون: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer

المصدر: Acta clinica Belgica, Vol. 74, no. 3, p. 180-188 (2019)

مصطلحات موضوعية: Adult, Male, renal cell carcinoma, endocrine system, endocrine system diseases, Abcg2, thyroid dysfunction, efflux pumps, sunitinib, Vascular Endothelial Growth Factor Receptor, Antineoplastic Agents, urologic and male genital diseases, Polymorphism, Single Nucleotide, 03 medical and health sciences, 0302 clinical medicine, Hypothyroidism, Thyroid dysfunction, Renal cell carcinoma, Sunitinib, medicine, ATP Binding Cassette Transporter, Subfamily G, Member 2, Humans, 030212 general & internal medicine, Adverse effect, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Aged, Aged, 80 and over, biology, business.industry, General Medicine, Middle Aged, medicine.disease, Kidney Neoplasms, Neoplasm Proteins, respiratory tract diseases, 030220 oncology & carcinogenesis, Cancer research, biology.protein, Female, Efflux, polymorphisms, business, Tyrosine kinase, medicine.drug

وصف الملف: Print-Electronic

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4534306ad4f33cdec43464b67e91e349
https://doi.org/10.1080/17843286.2018.1477229

PDF full text from Publisher

5

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

المؤلفون: H Miles Prince, Youn H Kim, Steven M Horwitz, Reinhard Dummer, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Jose A Sanches, Pablo L Ortiz-Romero, Oleg E Akilov, Larisa Geskin, Judith Trotman, Kerry Taylor, Stephane Dalle, Michael Weichenthal, Jan Walewski, David Fisher, Brigitte Dréno, Rudolf Stadler, Tatyana Feldman, Timothy M Kuzel, Yinghui Wang, Maria Corinna Palanca-Wessels, Erin Zagadailov, William L Trepicchio, Wenwen Zhang, Hui-Min Lin, Yi Liu, Dirk Huebner, Meredith Little, Sean Whittaker, Madeleine Duvic, David Joske, H. Miles Prince, Ian D. Lewis, Constanze Jonak, Franz Trautinger, Oliver Bechter, Dominique Bron, Vladmir Claudio C. de Lima, Jose Antonio Sanches, Richard Klasa, Martine Bagot, Marie Beylot-Barry, Michel D'Incan, Brigitte Dreno, Florent Grange, Jan Nicolay, Marion Wobser, Chalid Assaf, Carmen Loquai, Michele Spina, Alberto Bosi, Pier Paolo Fattori, Aleksandra Grzanka, Andres Lopez-Hernandez, Pablo L. Ortiz-Romero, Jose Juan Rifon Roca, Silvana Novelli Canales, Timothy Illidge, Rod Johnson, Stephen Morris, Pam McKay, Oleg Akilov, Steve Horwitz, Youn H. Kim, Barbara Pro, Timothy Kuzel, Adam Lerner, Herbert Eradat, Lubomir Sokol, David C. Fisher, Sarah Hughey

المساهمون: Prince, H. Mile, Kim, Youn H, Horwitz, Steven M, Dummer, Reinhard, Scarisbrick, Julia, Quaglino, Pietro, Zinzani, Pier Luigi, Wolter, Pascal, Sanches, Jose A, Ortiz-Romero, Pablo L, Akilov, Oleg E, Geskin, Larisa, Trotman, Judith, Taylor, Kerry, Dalle, Stephane, Weichenthal, Michael, Walewski, Jan, Fisher, David, Dréno, Brigitte, Stadler, Rudolf, Feldman, Tatyana, Kuzel, Timothy M, Wang, Yinghui, Palanca-Wessels, Maria Corinna, Zagadailov, Erin, Trepicchio, William L, Zhang, Wenwen, Lin, Hui-Min, Liu, Yi, Huebner, Dirk, Little, Meredith, Whittaker, Sean, Duvic, Madeleine

المصدر: The Lancet. 390:555-566

مصطلحات موضوعية: medicine.medical_specialty, Immunoconjugates, Cutaneous T-cell lymphoma, Population, Primary cutaneous anaplastic large cell lymphoma, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Quality of life, immune system diseases, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Humans, Medicine, Brentuximab vedotin, education, Brentuximab Vedotin, Bexarotene, Mycosis fungoides, education.field_of_study, business.industry, Medicine (all), General Medicine, medicine.disease, Lymphoma, T-Cell, Cutaneous, Surgery, 030220 oncology & carcinogenesis, Quality of Life, Neoplasm Recurrence, Local, business, medicine.drug

وصف الملف: STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cce0ee405e66e583edbdaab74473710c
https://doi.org/10.1016/s0140-6736(17)31266-7

View record from ScienceDirect

Find this article in full text from ProQuest

Full Text via ClinicalKey

6

Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination

المؤلفون: Oliver Bechter, Pascal Wolter, Aljosja Rogiers

المصدر: Melanoma Research. 27:164-167

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Pyridones, medicine.medical_treatment, Pyrimidinones, Dermatology, Disease-Free Survival, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Melanoma, Response Evaluation Criteria in Solid Tumors, Retrospective Studies, Trametinib, business.industry, MEK inhibitor, Imidazoles, Retrospective cohort study, Dabrafenib, Middle Aged, medicine.disease, Surgery, 030104 developmental biology, 030220 oncology & carcinogenesis, Retreatment, Cutaneous melanoma, Disease Progression, Female, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61e5eb5bd0b7cb5a99174dda5df5520f
https://doi.org/10.1097/cmr.0000000000000320

7

Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib

المؤلفون: Evelyne Lerut, Vincent Verschaeve, Diether Lambrechts, A. Mejean, Thomas Van Brussel, Gabrielle Couchy, Stéphane Oudard, Patrick Schöffski, Jessica Zucman-Rossi, Vincent Richard, Herlinde Dumez, Annelies Verbiest, Maxime Vanmechelen, Benoit Beuselinck, Pascal Wolter, Jean-Pascal Machiels, Maarten Albersen, Philip R. Debruyne

المساهمون: Leuven Center for Cancer Biology (VIB-KU-CCB), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven)-Vlaams Instituut voor Biotechnologie [Ghent, Belgique] (VIB), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Génomique Fonctionnelle des Tumeurs Solides (U1162), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of General Medical Oncology [Leuven], University Hospitals Leuven [Leuven], Anglia Ruskin University (ARU), CHU Ambroise Paré [Mons, Belgium], Grand Hôpital de Charleroi [Belgium], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), St. Nikolaus-Hospital Eupen [Eupen, Belgium], UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Unité d'oncologie médicale, CCSD, Accord Elsevier

المصدر: Clinical Genitourinary Cancer
Clinical Genitourinary Cancer, Elsevier, 2019, 17 (2), pp.e235-e246. ⟨10.1016/j.clgc.2018.11.002⟩
Clinical genitourinary cancer, Vol. 17, no. 2, p. e235-e246 (2019)
Clinical genitourinary cancer, Vol. 17, no.2, p. e235-e246 (2019)

مصطلحات موضوعية: Oncology, Adult, Male, medicine.medical_specialty, Genotype, Urology, 030232 urology & nephrology, Angiogenesis inhibitor, Polymorphism, Single Nucleotide, Disease-Free Survival, Pazopanib, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, medicine, Sunitinib, Humans, Progression-free survival, Neoplasm Metastasis, Receptor, Fibroblast Growth Factor, Type 2, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Germ-Line Mutation, Aged, Retrospective Studies, Outcome, Aged, 80 and over, Fibroblast growth factor receptor 2, business.industry, Hazard ratio, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Biomarker, Single nucleotide polymorphisms, Middle Aged, medicine.disease, Prognosis, Kidney Neoplasms, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, 3. Good health, Clear cell renal cell carcinoma, Treatment Outcome, 030220 oncology & carcinogenesis, Female, business, medicine.drug